Hope on the Horizon: Glycomine Trial Marks Major Step for Rare Disease

SAN CARLOS, Calif. – April 02, 2026 – In a significant development for the rare disease community, Glycomine, Inc. today announced it has completed patient enrollment for its pivotal Phase 2b POLAR study. The global trial is evaluating GLM101, a novel investigational therapy for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), a severe genetic condition with no currently approved treatments. The milestone marks a critical step forward in the quest to provide the first-ever therapy for the thousands of patients worldwide affected by this debilitating disease.

For families navigating a PMM2-CDG diagnosis, the journey is often one of uncertainty and constant medical challenges. The completion of enrollment means the study is now fully underway, bringing the promise of a potential treatment one step closer to reality. Topline data from the study is expected in the fourth quarter of 2026.

The Devastating Impact of a Hidden Disease

PMM2-CDG, the most common congenital disorder of glycosylation, is caused by a genetic defect that cripples the body's ability to properly attach sugar molecules to proteins—a fundamental process known as N-glycosylation. This disruption affects countless proteins and systems throughout the body, leading to a wide and unpredictable array of severe health problems.

While considered rare, PMM2-CDG is estimated to affect as many as 50,000 people globally. The condition typically manifests in infancy with symptoms like failure to thrive, developmental delays, and low muscle tone. For many, the most significant challenge is ataxia, a severe lack of voluntary coordination of muscle movements that affects over 90% of patients. This neurological symptom impairs balance, speech, and the ability to perform everyday tasks, with many individuals unable to walk independently.

The neurological impairments are just one facet of this multisystemic disorder. Patients can also suffer from liver and kidney disease, heart problems, clotting disorders, immune system dysfunction, and stroke-like episodes. The disease carries a high mortality rate, with up to 20% of affected children not surviving past the first few years of life. For those who survive into adulthood, they face a lifetime of complex medical needs and a significantly impacted quality of life, managed only by supportive care aimed at controlling symptoms.

A Novel Strategy to Mend a Broken Pathway

GLM101 represents a targeted approach to this complex disease. It is a substrate replacement therapy designed to bypass the genetic roadblock at the heart of PMM2-CDG. The therapy delivers mannose-1-phosphate (M1P), the very substrate that is deficient due to the faulty PMM2 enzyme.

To ensure the M1P reaches its destination, Glycomine has encapsulated it in a specialized lipid nanoparticle. This liposomal delivery system protects the molecule from degradation in the bloodstream and helps it cross into cells, including those in the central nervous system, to restore the glycosylation process. The treatment is administered as a weekly intravenous infusion.

This approach is built on promising earlier results. The company's prior open-label Phase 2a study, which was completed in 2025, provided the first glimpse of the drug's potential in patients.

“The Phase 2b POLAR study will build on the encouraging results observed in our open-label Phase 2a study of GLM101, which demonstrated meaningful improvements in ataxia and other clinical endpoints with a favorable safety profile,” said Rose Marino, M.D., Chief Medical Officer of Glycomine. “We are grateful to the patients, families, caregivers and investigators who have made these trials possible.”

The Gold Standard Test: Inside the POLAR Study

The POLAR study is a robust clinical trial designed to provide definitive evidence of GLM101's efficacy and safety. As a randomized, double-blind, placebo-controlled study, it is considered the gold standard in clinical research. This rigorous design means that neither the patients nor the investigators know who is receiving the active drug versus a placebo, minimizing bias and ensuring the results are scientifically sound.

The trial successfully enrolled 43 pediatric and adult patients, with ages ranging from 4 to 47, reflecting the lifelong nature of the disease. The global effort spans 15 trial sites across the United States, the United Kingdom, and Europe.

Over a 24-week period, participants will receive weekly infusions. The primary goal is to measure a change in ataxia using the International Cooperative Ataxia Rating Scale (ICARS), a comprehensive clinical tool for assessing coordination and balance. Researchers will also track a suite of secondary endpoints, including other ataxia scales like SARA and measures of gross motor function, to build a complete picture of the drug's potential benefits.

Navigating the Path to a Potential First-Ever Treatment

The development of GLM101 has been accelerated by several key regulatory designations, including Orphan Drug status in the U.S. and Europe, as well as Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration. These programs are designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need, acknowledging the urgency for patient communities like PMM2-CDG.

While other research efforts are exploring repurposed drugs or different therapeutic strategies, GLM101 stands out as a purpose-built substrate replacement therapy directly targeting the underlying biochemistry of the disease. The completion of enrollment in the POLAR study is a landmark achievement, not just for Glycomine but for the entire PMM2-CDG community that has long awaited a therapy designed specifically for them. With all participants now enrolled, the focus shifts to the careful execution of the trial and the anticipation of what the data will reveal in late 2026.